Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on LinkedIn:
” “Precision Oncology: Boon or Burden? — The LMIC Perspective”
Had the privilege of speaking at the 3rd Tanzania International Cancer Conference (TICC 2025) in Dar es Salaam, organized by the Tanzania Oncology Society, on a topic very close to my heart —
Can precision oncology truly be a boon for low- and middle-income countries, or does it risk becoming an unsustainable burden?
The discussion explored:
- Real-world barriers to molecular testing and access to targeted drugs
- The value equation — affordability vs. marginal benefit
- Opportunities for regional collaboration, registries, and pragmatic trials
- The promise of “Precision Public Health” as a bridge between equity and innovation
Precision means nothing if it doesn’t reach the last mile.
It was inspiring to engage with oncologists, researchers, and health leaders from across Africa, united by a shared goal — to make personalized cancer care truly accessible, not aspirational.
Grateful for the warm hospitality and thoughtful discussions at TICC2025.
sharing some of the pictures and some of my slides from my talk.”
More posts featuring Amol Akhade on OncoDaily.
